These ads enable local businesses to reach their target audience – the local community

It is important that we keep promoting these ads as our local businesses need as much support as possible during these challenging times

Coronavirus patients admitted to intensive care units will receive life-saving new treatments that can cut hospital stays by up to ten days, the government announced today

The results of the government-funded REMAP-CAP clinical trial published today showed that tocilizumab and sarilumab reduced the relative risk of death by 24 percent when administered to patients within 24 hours of ICU entry

Most of the data came from when the drugs were added to a corticosteroid such as dexamethasone, which was also discovered through government-sponsored research as part of the RECOVERY clinical trial, which is already being made available to the NHS as the standard of care for patients, Those who received these drugs, which are usually used to treat rheumatoid arthritis, left the intensive care unit an average of seven to ten days early

The introduction of these treatments could therefore go a long way in easing the pressure on hospitals in the weeks and months to come

Health and Welfare Secretary Matt Hancock said: “The UK has proven time and again that it is at the forefront of identifying and delivering the most promising and innovative treatments to its patients.” Today’s results mark another milestone in the search for a way out this pandemic When added to the vaccines and treatments already in place, they will play an important role in fighting this virus. “We worked quickly to make this treatment immediately available to NHS patients, which means hundreds of lives will be saved

“I am very proud of the significant role our NHS and its patients have played in this international study, and I thank the outstanding scientists and clinicians behind REMAP-CAP for bringing this treatment to our patients. The government and the NHS will have updated guidelines tomorrow for trusts across the UK to encourage them to use tocilizumab in their treatment of Covid-19 patients admitted to intensive care units, with immediate effect

Tocilizumab is already available in hospitals across the UK and doctors can treat any patient admitted to intensive care, potentially saving hundreds of lives

The Department of Health is working closely with Roche, which manufactures tocilizumab, to ensure patients in the UK continue to receive treatment. Deputy Chief Medical Officer Professor Jonathan Van-Tam said: “This is a significant step forward in ensuring patient survival in intensive care units to improve with COVID-19

“The data show that tocilizumab and probably sarilumab accelerate and improve the chances of recovery in the intensive care unit This is critical to relieving intensive care unit and hospitals pressure and saving lives

“This is proof that Britain’s excellent research infrastructure and life science industry is driving global understanding of this disease We achieved this through both our own clinical research program and our ability to make very large contributions to international studies. In June of last year, the UK government approved dexamethasone as the world’s first treatment proven to reduce mortality from Covid-19

The REMAP-CAP study found that the death rate in intensive care units using corticosteroids such as dexamethasone and respiratory support alone was 35 percent, which was reduced to 28 percent when tocilizumab was given

The government continues to work in partnership to ensure equitable access to safe and effective treatments worldwide

Only multilateral cooperation can achieve the speed and scale needed to end the global pandemic, and the government remains committed to participating in international studies like this one to answer key questions about the virus Britain has an important role to play in This international effort played: Three-quarters of patients enrolled worldwide were NHS patients in 142 hospitals across the UK – roughly half of the 289 locations worldwide

A quarter of all patients in the intensive care unit with Covid-19 have enrolled and continue to volunteer to participate in the REMAP-CAP study All of them have made an important contribution to research into this disease

Support also came from the UK’s National Institute for Health Research (NIHR), its well-established clinical research network, and the UK’s Chief Medical Officers

The UK government has so far allocated £ 1.2 million to support the REMAP-CAP study Professor Stephen Powis, National Medical Director of the NHS said: “The fact that there is now another drug that can help reduce patient mortality with Covid-19 is extremely good news and another positive development in the ongoing fight against the virus

“This signals how the NHS is constantly working to find new treatments and therapies However, the best advice for individuals is to remember their hands, face, and space management ”

Last updated:

This website and associated newspapers adhere to the Code of Conduct of the editors of the Independent Press Standards Organization.If you have a complaint about any editorial content relating to inaccuracies or tampering, please contact the editor here if you have any If you are not satisfied with the answer, you can contact IPSO here

© Copyright 2001-2021 This site is part of Newsquest’s Verified Local Newspaper Network A Gannett Company Newsquest Media Group Ltd, Loudwater Mill, Station Road, High Wycombe, Buckinghamshire HP10 9TY | 01676637 | Registered in England & Wales

Tocilizumab

World News – UK – Breakthrough life-saving Covid treatment cuts hospital time by ten days and reduces risk of death

Source: https://www.thenorthernecho.co.uk/news/18994621.remap-cap-clinical-trial-uses-tocilizumab-sarilumab-treat-covid/